Latest News

FOLFIRI, Bevacizumab 10 mg Not More Effective Than 5 mg for Colorectal Cancer

FOLFIRI, Bevacizumab 10 mg Not More Effective Than 5 mg for Colorectal Cancer

Bevacizumab 10mg/kg plus FOLFIRI as second-line treatment did not prolong progression-free survival compared with 5mg/kg in colorectal cancer.

Pembrolizumab May Be More Effective, Safer Than Ipilimumab for Advanced Melanoma

Pembrolizumab May Be More Effective, Safer Than Ipilimumab for Advanced Melanoma

Pembrolizumab better prolonged progression-free survival and overall survival than did ipilimumab in advanced melanoma.

Oral S-1 May Be Non-Inferior to Docetaxel for Non-Small Cell Lung Cancer

Oral S-1 May Be Non-Inferior to Docetaxel for Non-Small Cell Lung Cancer

Oral S-1 with cisplatin may not be inferior compared to docetaxel with cisplatin in advanced non-small cell lung cancer (NSCLC).

Cyramza Plus FOLFIRI Approved for Metastatic Colorectal Cancer

Cyramza Plus FOLFIRI Approved for Metastatic Colorectal Cancer

The FDA announced approval of CYRAMZA (ramucirumab) for use in combination with FOLFIRI for metastatic colorectal cancer.

POMALYST Meets Accelerated Approval Requirements for Multiple Myeloma

POMALYST Meets Accelerated Approval Requirements for Multiple Myeloma

POMALYST for relapsed/refractory multiple myeloma has met its accelerated approval requirements.

Breast Cancer Patients Eligible for Lumpectomy Still Choose Mastectomy

Breast Cancer Patients Eligible for Lumpectomy Still Choose Mastectomy

Many breast cancer patients who are eligible for breast-conserving surgery still choose to have the entire breast removed.

Colorectal Cancer Screening in Older Adults Often Inappropriate

Colorectal Cancer Screening in Older Adults Often Inappropriate

Older adults with limited life expectancy (LE) frequently receive colorectal cancer (CRC) screening.

Two Novel Technologies Show Promise in Cancer Treatment

Two Novel Technologies Show Promise in Cancer Treatment

Two new devices may eventually lead to more accurate, less toxic methods of predicting how well specific cancer drug might work.

Oophorectomy Linked to Better Survival in BRCA1 Breast Cancer

Oophorectomy Linked to Better Survival in BRCA1 Breast Cancer

Oophorectomy is associated with a decrease in mortality in women with breast cancer and a BRCA1 mutation.

In Breast Cancer, Self-Reported Health Predicts Survival

In Breast Cancer, Self-Reported Health Predicts Survival

For older women with breast cancer, low self-rated health (SRH) and limited walking ability predict worse all-cause survival at five and 10 years.

Second Primaries in Nearly Quarter of Metastatic Prostate Cancer Cases

Second Primaries in Nearly Quarter of Metastatic Prostate Cancer Cases

More than one-quarter of patients with metastatic prostate cancer present with a synchronous second primary malignancy.

Nivolumab, Ipilimumab More Effective Than Ipilimumab Alone for Melanoma

Nivolumab, Ipilimumab More Effective Than Ipilimumab Alone for Melanoma

Response rate and progression-free survival in untreated advanced melanoma significantly greated with nivolumab plus ipilimumab.

Pembrolizumab Safe, Shows Activity for Advanced Lung Cancer

Pembrolizumab Safe, Shows Activity for Advanced Lung Cancer

Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC).

Better Colorectal Cancer Surgery Outcomes with Higher-Volume Providers

Better Colorectal Cancer Surgery Outcomes with Higher-Volume Providers

Patients with colorectal cancer who undergo surgery at higher-volume providers may face better outcomes.

Outcome of Salpingectomy Alone for Ovarian Cancer Evaluated

Outcome of Salpingectomy Alone for Ovarian Cancer Evaluated

Salpingectomy alone may be a risk management option for women at hereditary risk of ovarian cancer.

Metformin Benefit Lacking in Pancreatic Ductal Cancer

Metformin Benefit Lacking in Pancreatic Ductal Cancer

New study finds that metformin doesn't help patients with pancreatic ductal adenocarcinoma (PDAC).

Under, Over Imaging Suspected for Prostate Cancer Care

Under, Over Imaging Suspected for Prostate Cancer Care

There may be under imaging in those at high risk for prostate cancer and over imaging in those at low risk.

Nivolumab Shows Encouraging Survival Rates in Heavily Pretreated Lung Cancer

Nivolumab Shows Encouraging Survival Rates in Heavily Pretreated Lung Cancer

Nivolumab monotherapy produced durable responses and encouraging survival rates in patients with heavily pretreated non-small cell lung cancer (NSCLC).

Nilotinib Less Effective Than Imatinib to Treat First-Line Gastrointestinal Tumors

Nilotinib Less Effective Than Imatinib to Treat First-Line Gastrointestinal Tumors

Nilotinib cannot be recommended for broad use as the first-line treatment of patients with gastrointestinal stromal tumors (GISTs).

Donepezil May Improve Several Cognitive Functions After Brain Irradiation

Donepezil May Improve Several Cognitive Functions After Brain Irradiation

Donepezil slightly improves several cognitive functions in brain tumor survivors who have undergone irradiation.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs